MSLN and neoplasm: Our team has also demonstrated the specificity of the 89Zr-labeled anti-MSLN-mAb in MSLN-positive and MSLN-negative tumor mice model via PET imaging compared to the 89Zr- and ICG-labelled Lactosome particles (Figure 2), spearheading the possibility of 89Zr-labeled anti-MSLN-mAb as a novel antibody-based therapy.